Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Department of Cardiovascular Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Am J Cardiol. 2020 Mar 1;125(5):772-776. doi: 10.1016/j.amjcard.2019.12.003. Epub 2019 Dec 9.
Elevated serum uric acid (UA) is associated with an increased risk of cardiovascular disease and worse clinical outcome in patients with cardiovascular disease. Nevertheless, the prognostic value of serum UA level in hospitalized heart failure patients with preserved ejection fraction (HFpEF) has not been fully elucidated. The aim of this study was to investigate whether serum UA level on admission could be associated with subsequent mortality in hospitalized patients with HFpEF. We examined 516 consecutive hospitalized HFpEF (left ventricular ejection fraction ≥50%) patients with decompensated heart failure from our HFpEF-specific multicenter registry who had serum UA data on admission. The primary outcome of interest was all-cause death. During a median follow-up period of 749 (interquartile range 540 to 831) days, 90 (17%) patients died. Higher serum UA level was significantly related to increased incidence of all-cause death (p = 0.016). In addition, patients with higher serum UA (≥6.6 mg/dl, median) and plasma B-type natriuretic peptide (≥401.2 pg/ml, median) levels had the highest incidence of all-cause death in the groups (p = 0.002). In multivariable Cox regression analysis, serum UA was an independent determinant of mortality (hazards ratio 1.23, 95% confidence interval 1.10 to 1.39) even after adjustment for prespecified confounders, renal function and the use of diuretics before admission. In conclusions, higher admission serum UA was an independent determinant of mortality in hospitalized HFpEF patients. Our findings indicate the importance of assessing admission serum UA level for further risk stratification in hospitalized patients with HFpEF.
血清尿酸(UA)水平升高与心血管疾病患者心血管疾病风险增加和临床预后恶化相关。然而,血清 UA 水平在射血分数保留的心力衰竭(HFpEF)住院患者中的预后价值尚未完全阐明。本研究旨在探讨入院时血清 UA 水平是否与 HFpEF 住院患者的后续死亡率相关。我们检查了来自 HFpEF 特异性多中心登记处的 516 例连续住院 HFpEF(左心室射血分数≥50%)合并失代偿性心力衰竭且入院时具有血清 UA 数据的患者。主要研究终点为全因死亡。在中位随访 749 天(四分位距 540 至 831 天)期间,90 例(17%)患者死亡。较高的血清 UA 水平与全因死亡率增加显著相关(p=0.016)。此外,血清 UA(≥6.6mg/dl,中位数)和血浆 B 型利钠肽(≥401.2pg/ml,中位数)水平较高的患者在各亚组中的全因死亡率最高(p=0.002)。多变量 Cox 回归分析显示,在校正了预先指定的混杂因素、肾功能和入院前利尿剂的使用后,血清 UA 是死亡率的独立决定因素(危险比 1.23,95%置信区间 1.10 至 1.39)。结论:入院时较高的血清 UA 是 HFpEF 住院患者死亡的独立决定因素。我们的研究结果表明,评估入院时血清 UA 水平对 HFpEF 住院患者进行进一步危险分层的重要性。